Sunshine Biopharma Inc Dossier - Source-backed chat

Sunshine Biopharma Inc

SBFMNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.19

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.69Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.7M

Enterprise Value −$6.5M

Shares Outstanding 3.9M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sunshine Biopharma Inc. (SBFM) presents a unique hybrid business model combining a revenue-generating Canadian generic drug business (Nora Pharma) with high-risk, high-reward proprietary oncology and antiviral R&D programs. While Nora Pharma provides a foundational commercial footprint with 60 marketed generic drugs, recent Q1 2026 results show a 9% year-over-year revenue decline to $8.1 million and a gross margin contraction to 27% due to the termination of certain distribution agreements. The company remains unprofitable, posting a net loss of $1.24 million in Q1 2026. Although management's cost-reduction initiatives target $2-3 million in annual G&A savings, and a recent 1-for-10 reverse stock split on June 1, 2026, temporarily resolved Nasdaq listing compliance issues, the stock remains highly speculative. Investors are advised to Hold, monitoring the execution of 12 planned generic drug launches in 2026 and preclinical progress of its proprietary pipeline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$56.00

Mean target$56.00

High · most bullish analyst$56.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.4520%

New generic drug launches face regulatory delays or slow market uptake in Canada, while pricing pressure and wholesaler fees further erode gross margins below 25%. G&A cost-reduction targets are not fully realized, resulting in an accelerated cash burn rate that depletes the company's cash reserves faster than the estimated 17-month runway. This forces highly dilutive equity offerings or warrant adjustments, putting downward pressure on the stock price and risking another Nasdaq minimum bid price violation.

Base CaseCentral scenario

$2.2055%

Nora Pharma maintains steady-state operations, with revenue growing modestly to approximately $39.1 million in 2026 as new generic launches offset pricing pressure and the loss of terminated distribution agreements. Gross margins stabilize around 30-32%, and net losses persist but narrow due to G&A cost savings. Preclinical R&D continues at a measured pace without major clinical trial initiations or partnerships in the near term. The stock trades in line with micro-cap biotech peers, supported by its cash cushion of ~$6.9 million.

Bull CaseUpside scenario

$5.6025%

Nora Pharma successfully launches 12+ new generic drugs in 2026, expanding its Canadian footprint and driving revenues past $40 million while restoring gross margins to the 35% range. Concurrently, cost-reduction initiatives successfully shave $3 million off annual G&A, bringing the company close to operational breakeven. In the proprietary pipeline, preclinical studies for K1.1 mRNA (liver cancer) and PLpro protease inhibitors yield highly positive data, attracting a major pharmaceutical partner and securing non-dilutive upfront licensing payments.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Hybrid business model with a real commercial generics business (Nora Pharma) that mitigates pure clinical-stage biotech risk.
Established portfolio of 60 generic prescription drugs in Canada with a clear roadmap to launch 12 additional products in 2026.
Solid cash position of $6.91 million as of March 31, 2026, with no long-term debt beyond lease liabilities, providing an estimated 17-month runway.
Proprietary pipeline targeting high-value indications, including K1.1 mRNA for liver cancer and PLpro protease inhibitors for SARS-related coronaviruses.

Key Investment Risks

Highly concentrated voting control, with CEO Dr. Steve N. Slilaty holding approximately 86% of the total voting power.
History of persistent net losses ($5.98 million in FY2025 and $1.24 million in Q1 2026) with no clear timeline to GAAP profitability.
Pricing pressure and regulatory hurdles in the Canadian generic drug market, as evidenced by the Q1 2026 gross margin contraction to 27%.
Risk of future equity dilution, highlighted by recent public offerings and shareholder approval for dilutive warrant adjustments.

Thesis Invalidation Triggers

Failure to launch the planned 12 generic drugs in 2026, leading to stagnant or declining top-line revenue.
Gross margins falling below 25% on a sustained basis, indicating severe pricing pressure or operational inefficiencies.
A rapid increase in quarterly cash burn exceeding $2.5 million, significantly shortening the estimated 17-month runway.
Negative preclinical data readouts or safety concerns regarding the K1.1 mRNA or PLpro protease inhibitor programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.